Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 May;21(5):846–847. doi: 10.1128/aac.21.5.846

In Vitro Susceptibility of Clostridium difficile Isolates to Cefotaxime, Moxalactam, and Cefoperazone

Ronald A Greenfield 1, Terrence A Kurzynski 2, William A Craig 1
PMCID: PMC182026  PMID: 6285817

Abstract

The in vitro susceptibility of 20 isolates of Clostridium difficile to cefotaxime, moxalactam, and cefoperazone was determined by a standard agar dilution method. The median minimal inhibitory concentrations were 64, 32, and 32 μg/ml for cefotaxime, moxalactam, and cefoperazone, respectively.

Full text

PDF
846

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett J. G. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea of colitis. Johns Hopkins Med J. 1981 Jul;149(1):6–9. [PubMed] [Google Scholar]
  2. Bartlett J. G., Willey S. H., Chang T. W., Lowe B. Cephalosporin-associated pseudomembranous colitis due to Clostridium difficile. JAMA. 1979 Dec 14;242(24):2683–2685. [PubMed] [Google Scholar]
  3. Craig W. A., Gerber A. U. Pharmacokinetics of cefoperazone: a review. Drugs. 1981;22 (Suppl 1):35–45. doi: 10.2165/00003495-198100221-00010. [DOI] [PubMed] [Google Scholar]
  4. Dzink J., Bartlett J. G. In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother. 1980 Apr;17(4):695–698. doi: 10.1128/aac.17.4.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ebright J. R., Fekety R., Silva J., Wilson K. H. Evaluation of eight cephalosporins in hamster colitis model. Antimicrob Agents Chemother. 1981 Jun;19(6):980–986. doi: 10.1128/aac.19.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. George W. L. Antimicrobial agent-associated colitis and diarrhea. West J Med. 1980 Aug;133(2):115–123. [PMC free article] [PubMed] [Google Scholar]
  7. George W. L., Sutter V. L., Citron D., Finegold S. M. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol. 1979 Feb;9(2):214–219. doi: 10.1128/jcm.9.2.214-219.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gerber A. U., Craig W. A. Worldwide clinical experience with cefoperazone. Drugs. 1981;22 (Suppl 1):108–118. doi: 10.2165/00003495-198100221-00022. [DOI] [PubMed] [Google Scholar]
  9. Hutcheon D. F., Milligan F. D., Yardley J. H., Hendrix T. R. Cephalosporin-associated pseudomembranous colitis. Am J Dig Dis. 1978 Apr;23(4):321–326. doi: 10.1007/BF01072414. [DOI] [PubMed] [Google Scholar]
  10. Leroy A., Humbert G., Fillastre J. P. Pharmacokinetics of moxalactam in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 1981 Jun;19(6):965–971. doi: 10.1128/aac.19.6.965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lüthy R., Münch R., Blaser J., Bhend H., Siegenthaler W. Human pharmacology of cefotaxime (HR 756), a new cephalosporin. Antimicrob Agents Chemother. 1979 Aug;16(2):127–133. doi: 10.1128/aac.16.2.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rolfe R. D., Finegold S. M. Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother. 1981 Nov;20(5):600–609. doi: 10.1128/aac.20.5.600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Tofte R. W., Rotschafer J., Solliday J., Crossley K. B. Moxalactam therapy for a wide spectrum of bacterial infections in adults. Antimicrob Agents Chemother. 1981 May;19(5):740–744. doi: 10.1128/aac.19.5.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tures J. F., Townsend W. F., Rose H. D. Cephalosporin-associated pseudomembranous colitis. JAMA. 1976 Aug 23;236(8):948–949. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES